A Surgeon Just Performed Hip Surgery Wearing Apple Vision Pro
Dr. Chad Mather III at Duke Health performed hip surgery using Apple Vision Pro with Stryker’s FDA-authorized SportSuite Vision app, displaying critical data in the surgeon’s field of view. The FDA granted De Novo authorization for this use on July 17, 2026, classifying it as a Class II orthopedic device. This marks the first real-world clinical use of such technology, announced on September 1, 2026.
How this was made
The 30-second read
Why it matters
The approval could validate mixed‑reality technology in surgery, encouraging further investments in similar solutions.
Market read
Regulatory approval for AR surgical tools may create new growth avenues for med‑tech firms.
What to watch
Potential reimbursement challenges and need for hospital integration.
Background
Apple Vision Pro, a high‑cost mixed‑reality headset, has struggled to find consumer traction; this FDA clearance marks its first clinical application.
Ticker impact
Stryker's SportSuite Vision app received FDA De Novo authorization for intra‑operative use on Apple Vision Pro.
Possible modest upside as investors price in new product opportunity.
First FDA approval for a consumer headset in surgery; limited to two hip procedures but opens a new market segment.
Market effects
May spur interest in AR/VR solutions for medical devices across the healthcare technology sector.
Highlights US medical device innovation, could benefit domestic suppliers.
Sets precedent for consumer AR hardware use in regulated clinical settings worldwide.
Counterpoint
Adoption may be slow due to high headset cost and limited procedure scope.
Key entities
- CompanyApple Inc.
Manufacturer of the Vision Pro headset used in the procedure.
- InstitutionDuke Health
Hospital where the first intra‑operative use was performed.
